ArticleLipids in health and disease2020
Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study.
Article in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Application of Multivariate Adaptive Regression Splines to Estimate Fatty Liver Index in Healthy Young Taiwanese Men.Diagnostics (Basel, Switzerland) · 2026Article
- Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways.Clinical science (London, England : 1979) · 2025Review
- Association between blood glucose indicators and metabolic diseases in the Chinese population: A national cross-sectional study.Chinese medical journal · 2025Article
- Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact.Journal of health, population, and nutrition · 2025Article
- Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease.Lipids in health and disease · 2025Article
- Article
- The fasting plasma glucose to high-density lipoprotein cholesterol ratio: a novel index for identifying NAFLD.BMC gastroenterology · 2025Article
- Predictive value of triglyceride glucose index in non-obese non-alcoholic fatty liver disease.BMJ open · 2025Observational
- Global burden of NAFLD 1990-2021 and projections to 2035: Results from the Global Burden of Disease study 2021.PloS one · 2025Article
- Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts.Frontiers in nutrition · 2025Article
- Impact of Diets Supplemented With Low Glycemic Index Starch on Physiology and Locomotor Abilities of Mice.Journal of toxicology · 2025Article
- Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study.BMJ open gastroenterology · 2024Article
- Machine-Learning Application for Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease Using Laboratory and Body Composition Indicators.Archives of Iranian medicine · 2024Article
- Development and validation of a machine learning-based framework for assessing metabolic-associated fatty liver disease risk.BMC public health · 2024Article
- Nonlinear relationship between the triglyceride-glucose index and alanine aminotransferase in children with short stature.Scientific reports · 2024Article
- Two-week continuous glucose monitoring-derived metrics and degree of hepatic steatosis: a cross-sectional study among Chinese middle-aged and elderly participants.Cardiovascular diabetology · 2024Article
- Efficacy of Adding Sitagliptin to Ongoing Metformin on Metabolic Profile, Triglyceride-Glucose Index, Vitamin D3, and Liver Tests in Patients Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial.Current therapeutic research, clinical and experimental · 2024Article
- Clinical Characteristics, Risk Factors, and Predictors of Nonobese Fatty Liver Disease: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Early but Not Late Exercise Training in Mice Exacerbates Hepatic Inflammation in Developing Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFasting plasma glucose (FPG) is an easily quantifiable and inexpensive metabolic marker, which is often used to assess cardiovascular disease and diabetes. However, there have been limited studies on the association between FPG and nonalcoholic fatty liver disease (NAFLD) risk in nonobese people, especially in Chinese individuals. The purpose of this study was to investigate the association between FPG and NAFLD in nonobese Chinese people with normal blood lipid levels.
methodsIn this prospective cohort study, 9767 nonobese participants with normal blood lipid levels without NAFLD were recruited and prospectively followed for 5 years. The Cox proportional hazard model was used to evaluate the risk factors of NAFLD. Moreover, a Cox model with cubic spline functions and smooth curve fitting (the cubic spline smoothing) were used to identify the nonlinear association between FPG and NAFLD.
resultsDuring the 5-year follow-up, 841 (8.61%) participants were diagnosed with NAFLD. The good functional results (without NAFLD) estimated by the Kaplan-Meier method for 1 year, 2 years, 3 years, 4 years, and 5 years were 98.84, 95.35, 91.67%, 87.57 and 74.86%, respectively. Additionally, through the Cox proportional hazard model, after adjusting for other covariates, there was an independent positive correlation between FPG and increased NAFLD risk (HR:1.21, 95% CI:1.15-1.28, P < 0.0001), and the NAFLD risk was incrementally higher with the rising FPG quartile. The nonlinear association between FPG and NAFLD was visualized by cubic spline smoothing technique. It was calculated that the inflection point of FPG was 5.54. When FPG ≤ 5.54, there was a positive correlation between FPG and the risk of NAFLD (HR:2.20, 95% CI:1.78-2.73, P < 0.0001). When FPG > 5.54, the risk of NAFLD increased by 50% (HR:1.10, 95% CI:1.02-1.18, P = 0.0159) compared with the left side of the inflection point and gradually leveled off.
conclusionsIn a nonobese Chinese population with normal lipid levels, there is an independent nonlinear association between FPG and NAFLD, and the increase in FPG may indicate an increased risk of NAFLD. Additionally, this independent association is more obvious in the short stature population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.